SEC Form 3 · accession 0001144204-16-074085
IMMUNE PHARMACEUTICALS INC · IMNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Militello
Officer — See Remarks
Period of report
Dec 31, 2015
Accepted (ET)
Jan 5, 2016 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001208261
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 2,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $1.98 | holding | — | — | — | — | Apr 27, 2025 | Common Stock | 65,000 | — | D |
| Stock OptionF2 | $1.84 | holding | — | — | — | — | Jul 9, 2025 | Common Stock | 10,000 | — | D |
Explanation of responses
- F120,000 of the stock options vested on the grant date, 15,000 of the stock options vesting on the first anniversary of the date of grant and the remainder vesting quarterly over the following two-year period.
- F2The stock options shall vest over a period of three years, with 3,333 of the options vesting on the first anniversary of the date of grant and the remainder vesting quarterly over the following two-year period.
Remarks
Title: Vice President of Finance, Controller and Chief Accounting Officer (Principal Financial Officer) // Exhibit List - Exhibit 24 - Power of Attorney